Skip to main content

Sessions

Download programme

Download PDF

Programme

5th Central European Biomedical Congress, Kraków, Poland,
May 29 – June 1, 2023, Future trends in health interventions
Venue: Auditorium Maximum, 33 Krupnicza Street, Krakow, Poland

Monday, May 29, 2023
9.00 a.m. – 5.00 p.m. Registration
9.30 – 10.30 a.m. – Medium Hall A + B Plenary lecture
Professor Gustavo Turecki PhD, MD
Douglas Hospital Research Centre, McGill Group for Suicide Studies, Montreal, Quebec, Canada
Molecular Mediators of Antidepressant Response
Chairpersons: Professor Marta Dziedzicka-Wasylewska, PhD; Agata Faron-Górecka, PhD
10.30 – 11.15 a.m. – Medium Hall A + B Center for New Pharmacotherapies of the Central Nervous System Diseases – CEPHARES – a new R&D division of the Maj Institute of Pharmacology
Mission, opportunities, perspectives
Grzegorz Kreiner, PhD, Professor Andrzej Bojarski, PhD
Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
KAWA.SKA presentation
Jarosław Korczyński, PhD
11.15 – 11.45 a.m. – Exhibition Room Coffee break
11.45 – 1.15 p.m. – Medium Hall A or B Session 1: Blood-brain barrier dysfunction in CNS disorders Session 2: Mass spectrometry in medical sciences
Chairpersons: Professor Marta Dziedzicka-Wasylewska, PhD; Agata Faron-Górecka, PhD Chairperson: Przemysław Mielczarek, PhD
S. 01-1 S. 02-1
Professor Marta Dziedzicka-Wasylewska, PhD Professor Giuseppe Grasso, PhD
Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland University of Catania, Catania, Italy
Potential role of blood-brain barrier in stress resilience The use of mass spectrometry in conformational diseases
S. 01-2 S. 02-2
Agnieszka Chocyk, PhD Professor Vladimir Havlicek, PhD
Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic
Sex-specific effects of early-life stress on blood-brain barrier function and response to immune challenge in rats Next generation infection diagnostics
S. 01-3 S. 02-3
Barbara Błasiak, PhD Professor Anna Bodzon-Kulakowska, PhD
Institute of Nuclear Physics, Polish Academy of Sciences, Kraków, Poland AGH University of Science and Technology, Kraków, Poland
MRI Contrast Agents Crossing Blood-Brain Barrier Cholesterol and glucose analysis using the mass spectrometry imaging approach
S. 02-4
Marta Gawin, PhD
Maria Sklodowska-Curie National Research, Institute of Oncology, Gliwice, Poland
Possibilities and challenges of MALDI mass spectrometry imaging in cancer research
1.15 – 2.45 p.m. – Medium Hall A or B Session 3: Theranostic nanocarriers for drug delivery in central nervous system disorders Session 4: Modern approaches in immunodiagnostics and immunotherapy
Chairpersons: Professor Władysław Lasoń, PhD; Professor Piotr Warszyński, PhD Chairperson: Professor Maciej Siedlar, PhD
S. 03-1 S. 04-1
Juan Yang, PhD Professor Gabriela Kania, PhD
Process Chemistry and Functional Materials, SINTEF, Oslo, Norway University of Zurich, Center of Experimental Rheumatology, Zurich, Switzerland
Progress of Engineered nanoparticls as theranostic nanocarriers Tale of two tubes exploring pathological mechanisms in systemic sclerosis – focus on monocytes and macrophages
S. 03-2 (recorded lecture) S. 04-2
William Louch, PhD Proffessor Marcin Majka, PhD
Oslo University Hospital, Oslo, Norway Institute of Paediatrics, Jagiellonian University Medical College, Kraków, Poland
Understanding cellular structure: function relationships with super-resolution microscopy Future of cell-based therapeutics in the light of today’s developments
S. 03-3 S. 04-3 (recorded lecture)
Krzysztof Szczepanowicz, PhD Professor Radosław Zagożdżon, PhD
Jerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Sciences, Kraków, Poland Department of Clinical Immunology, Medical University of Warsaw, Poland
Synthesis and characterization of polymer-based theranostic nanoparticles containing carnosic acid New directions in chimeric antigen receptor (CAR)-based immunotherapies
S. 03-4
Danuta Jantas, PhD
Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
Biosafety and neuroprotective potency of polymer-based theranostic nanoparticles containing carnosic acid
S. 03-5
Rugmani Meenambal, PhD
Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
Polyacrylic acid (PAA) conjugated cerium oxide nanoparticles as efficient neuroprotectants against oxidative stress-induced cell damage in human neuronal-like cells
2.45 – 3.15 p.m. – Exhibition Room Coffee break
3.15 – 3.30 p.m. – Large Hall A Welcome ceremony
Chairpersons: Honorary Committee & Organizing Committee
3.30 – 4.30 p.m. – Large Hall A Inaugural lecture
Professor Véronique Deroche Gamonet PhD, HDR
Neurocentre Magendie, University of Bordeaux, Bordeaux, France
Re-conceptualizing the modeling of drug addiction in animals – a translational perspective
Chairperson: Jan Rodriguez Parkitna, PhD
4.30 – 4.45 p.m. – Large Hall A Promotion of the city of Krakow and the Maj Institute of Pharmacology Polish Academy of Sciences
4.45 – 5.45 p.m. – Large Hall A Cellostrada Quintet concert
5.45 – 9.00 p.m. – Exhibition Room Welcome party
Tuesday, 30 May 2023
9.00 a.m. – 5.00 p.m. Registration
9.00 – 10.30 a.m. – Medium Hall A or B Session 5: The burden of neurodegenerative and psychiatric disorders: trends and future treatment Session 6: Sphingolipids in health and brain diseases
Chairperson: Professor Katarzyna Starowicz-Bubak, PhD Chairperson: Professor Christian P. Muller, PhD
S. 05-1 S. 06-1
Professor Aron H. Lichtman, PhD Professor Christian P. Muller, PhD
Virginia Commonwealth University, Richmond, VA, USA Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
Turning over a new leaf: investigation of endocannabinoid regulating Enzymes in a mouse model of
chemotherapy-induced pain
Sphingolipids in the brain: from memory control to psychiatric disorders
S. 05-2 S. 06-2
Professor Danilo De Gregorio, PhD Alessandro Prinetti, PhD
Vita-Salute University and San Raffaele Scientific Institute, Milan, Italy University of Milano, Italy
Therapeutic use of psychedelics in mental health Sphingolipids orchestrating the cross-talk between different cell populations in the formation of myelin and in the repair of damaged myelin
S. 05-3 S. 06-3
Iskra Pollak Dorocic, PhD Vittorio Maglione, PhD
SciLifeLab, Stockholm University, Stockholm, Sweden Neuromed, Pozzilli, Italy
Transcriptional effects of SSRI administration on brain networks Sphingolipid alterations in Huntington’s disease: new insights into molecular mechanisms and potential therapies
10.30 – 11.00 a.m. – Exhibition Room Coffee break
11.00 – 11.30 a.m. – Medium Hall A + B Polonium Fundation presentation
Agnieszka Gawda
11.30 – 12.30 p.m. – Medium Hall A + B Plenary lecture
Professor Kathryn A. Cunningham, PhD
University of Texas Medical Branch at Galveston, USA
Defining the Path to Maximize Therapeutics for Substance Use Disorders
Chairperson: Professor Władysław Lasoń, PhD
12.30 – 1.30 p.m. – Exhibition Room Poster session 1
12.30 – 1.30 p.m. – Exhibition Room Lunch break
1.30 – 3.00 p.m. – Medium Hall A or B Session 7: Innovative nanocarriers and treatment modalities in antitumor therapy Session 8: New targets, new ligands, new drugs: a novel approach for the treatment of the CNS pathologies
Chairperson: Professor Bożena Kamińska-Kaczmarek, PhD Chairpersons: Professor Małgorzata Kajta, PhD; Agnieszka Wnuk, PhD
S. 07-1 S. 08-1
Professor Bożena Kamińska-Kaczmarek, PhD Adib Zendedel, PhD
Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warsaw, Poland Institute of Neuroanatomy, Medical Faculty, RWTH Aachen University, Aachen, Germany
Reinvigorating antitumor immunity in brain tumors with short peptides and siRNA-nanocarriers targeting the
tumor microenvironment
The role of microglial-derived extracellular vesicles in the pathogenesis of traumatic spinal cord injury:
implication of exosomal microRNAs
S. 07-2 S. 08-2
Professor Ling Peng, PhD Professor Joanna Śliwowska, PhD
Aix-Marseille University, Marseille, France Poznań University of Life Sciences, Poznań, Poland
Modular and adaptive dendrimer nanosystems in cancer treatment Metabolic and reproductive dysfunctions associated with obesity and diabetes: From the womb to adulthood
S. 07-3 S. 08-3
Professor Tambet Teesalu, PhD Agnieszka Wnuk, PhD
University of Tartu, Tartu, Estonia Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
Targeting of nanoparticles with homing peptides Emerging evidence for triclocarban as a neurodevelopmental risk factor: disruption of epigenetic status and
dysregulation of neurogenesis-related genes
S. 08-4
Professor Małgorzata Kajta, PhD
Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
New treatment strategies against neural degenerations based on selective targeting of membrane estrogen
receptors and PPARγ
3.00 – 3.30 p.m. – Exhibition Room Coffee break
3.30 – 5.00 p.m. – Medium Hall A or B Session 9: Chaperons in Gaucher’s disease Session 10: Tracking brain projections and cell signaling involved in neuroadaptations triggered by cocaine, stress, or neurodegeneration
Chairperson: Professor Beata Kieć-Wilk, PhD Chairpersons: Grzegorz Kreiner, PhD; Agnieszka Zelek-Molik, PhD
S. 09-1 S. 10-1
Christine Serratice, PhD, MD Rachel J. Smith, PhD (recorded lecture)
Department of Internal Medicine, Geneva University Hospital, Geneva, Switzerland Texas A&M University, USA
Current treatment options and novel strategies for lysosomal storage disorder, like Gaucher disease Investigating the link between habitual cocaine seeking and punishment resistance in rat models of addiction
S. 09-2 S. 10-2
Professor Mia Horowitz, PhD Yonatan Kupchik
Schmunis School of Biomedicine and Cancer Research, Tel Aviv University, Tel Aviv, Israel The Institute for Medical Research Israel-Canada (IMRIC), The Hebrew University of Jerusalem, Israel
Chaperone as a therapeutic modality in Gaucher disease Multimodal differences between projections of the ventral pallidum and relevance to cocaine reward
S. 09-3 S. 10-3
Professor Ari Zimran, PhD, MD Agnieszka Zelek-Molik, PhD
Gaucher Unit, Shaare Zedek Medical Center, Jerusalem, Israel; Faculty of Medicine, Hebrew University, Jerusalem, Israel Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków
Chaperone treatment option in neuronopathic GD and GBA related Parkinson Psychosocial crowding stress affects neuroplasticity-related signalling pathways within rats’ frontal cortex in a
region-dependent manner
S.10-4
Justyna Barut, MSc
Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
Utilization of conditional single lentivirus CRISPR/Cas9 vector for efficient gene knockout generation in adult neurons in vivo and in vitro as potential new model for study prodromal phase of Parkinson’s disease
Wednesday, 31 May 2023
9.00 a.m. – 5.00 p.m. Registration
9.00 – 10.30 a.m. – Medium Hall A or B Session 11: Medical biotechnology in disease modelling, drug research and therapy Session 12: Novel rapid-acting antidepressants
Chairpersons: Professor Józef Dulak, PhD; Professor Agnieszka Łoboda, PhD Chairpersons: Bernadeta Szewczyk, PhD; Professor Andrzej Pilc, PhD
S. 11-1 S. 12-1
Professor Józef Dulak, PhD Professor Jeffrey M Witkin, PhD
Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland University of Wisconsin – Milwaukee, USA
Stem cells in neurological diseases modelling and therapies: possibilities, hopes and hypes New age antidepressants create new ways to think about treatment
S. 11-2 S. 12-2
Florence Rage, PhD Professor Laura Musazzi, PhD
Institute de Genetique Moleculaire, CNRS, Montpellier, France School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
From NMJ on a single chip to a Simplified Miniature Arrays (SMA) for drugs screening Molecular signature of ketamine – response/non-response in a preclinical model of depression
S. 11-3 S. 12-3
Sifeng Chen, PhD Professor Shigeyuki Chaki, PhD
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, Shanghai, People’s Republic of China Taisho Pharmaceutical, Japan
The therapeutic effects of induced pluripotent stem cells and their exosomes on cardiovascular diseases Ketamine-like antidepressant potential of mGlu2/3 receptor antagonists and progress of other candidates targeting the glutamatergic system
10.30 – 11.00 a.m. – Exhibition Room Coffee break
11.00 – 11.30 a.m. – Medium Hall A + B Celon Pharma S.A. presentation
Mikołaj Matłoka, PhD; Filip Mituła, PhD
11.30 – 12.30 p.m. – Medium Hall A + B Plenary lecture
Professsor Stefan Chłopicki, PhD, MD
Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland
Endothelial biomedicine and experimental pharmacology of endothelial dysfunction; a call for endothelium-guided diagnosis and therapy
Chairperson: Professor Joanna Pera, MD, PhD
12.30 – 1.30 p.m. – Exhibition Room Poster session 2
12.30 – 1.30 p.m. – Exhibition Room Lunch break
1.30 – 3.00 p.m. – Medium Hall A or B Session 13: Digital medicine – beyond diagnostics Session 14: Duchenne muscular dystrophy and its complications – new tools and mechanisms for possible
treatments
Chairperson: Klaudia Proniewska, PhD Chairpersons: Professor Agnieszka Łoboda, PhD; Professor Józef Dulak, PhD
S. 13-1 S. 14-1
Klaudia Proniewska, PhD Maurilio Sampaolesi, PhD
Jagiellonian University Medical College, Kraków, Poland KU Leuven, Leuven, Belgium
Medical 3D cardiac anatomy supported by Mixed Reality Harnessing novel 3D stem cell-based models to challenge dystrophic cardiomyopathy
S. 13-2 S. 14-2
Danila Potyagaylo Jacek Stępniewski
EPIQure GmbH, Nuremberg, Germany Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland
Novel Ways of Bringing Non-Invasive ECG Imaging into Clinical Practice Human induced pluripotent stem cells and gene editing for modelling of Duchenne muscular dystrophy-
associated cardiomyopathy
S. 13-3 S. 14-3
Peter van Dam Professor Agnieszka Łoboda, PhD
UMC Utrecht, Utrecht, the Netherlands Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland
The ventricular cineECG during acute Ischemia Hydrogen sulfide donors: therapeutic potential in Duchenne muscular dystrophy
S. 13-4
Professor Wiesław Nowiński, PhD
Sano Centre for Computational Personalised Medicine, Krakow, Poland
Future trends in human brain atlasing
3.00 – 3.30 p.m. – Exhibition Room Coffee break
3.30 – 5.00 p.m. – Medium Hall A + B Session 15: Future therapies with psychedelics
Chairperson: Professor Krystyna Gołembiowska, PhD
S. 15-1
Professor Charles Nichols, PhD
LSU Health Sciences Center, New Orleans, LA, USA
Psychedelics can produce persistent antidepressant-like effects, and changes in functional plasticity across several types of depression models
S. 15-2
Urszula Kozłowska, PhD
Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznań, Poland
Psychedelics immunomodulatory effect on microglia and its prospect meaning for neurodegenerative diseases treatment
8.00 – 11.00 p.m. Congress dinner – Kościuszko Mound in Kraków, 1 Washington Avenue
Thursday, 1 June 2023
9.00 a.m. – 2.00 p.m. Registration
9.00 – 10.00 a.m. – Medium Hall A + B Plenary lecture
Professor Stéphane Oliet, PhD
Neurocentre Magendie, University of Bordeaux, Bordeaux, France
Astroglial contribution to NMDA receptor activity
Chairperson: Katarzyna Głombik, PhD
10.00 – 11.00 a.m. – Medium Hall A + B Session 16: ERC presentation – A way to consolidate your research independence – presentations from successful ERC grant applicants
Chairperson: Janka Matrai, PhD
European Research Council Executive Agency, Brussels, Belgium
S. 16-1
Professor Ewa Chrostek, PhD
Jagiellonian University, Kraków, Poland
S. 16-2
Krzysztof Szade, PhD
Jagiellonian University, Kraków, Poland
11.00 – 11.30 a.m. – Exhibition Room Coffee break
11.30 – 1.00 p.m. – Medium Hall A + B Session 17: Magnificent Seven: on the role of the 5-HT7 receptor in the brain
Chairpersons: Monika Bijata, PhD, Professor Paweł Zajdel, PhD
S. 17-1
Séverine Morisset-Lopez, PhD
Center for Molecular Biophysics, CNRS, Orléans, France
Discovery of biased ligands of 5-HT7R to illuminate the receptor biology
S. 17-2
Professor Evgeni Ponimaskin, PhD
Hannover Medical School, Hannover, Germany
Targeting the serotonin receptor 7 (5-HT7R) ameliorates Tau pathology and memory deficits
S. 17-3
Professor Jakub Włodarczyk, PhD
Nencki Institute of Experimental Biology of Polish Academy of Science, Warsaw, Poland
The molecular fingerprint of stress resilience
1.00 -1.30 p.m. – Exhibition Room Coffee break
1.30 – 2.45 p.m. – Medium Hall A + B Session 18: Young scientific investigators’ session
Chairperson: Professor Agnieszka Łoboda, PhD, Professor Rafał Ryguła, PhD
2:45 – 3.15 p.m. – Medium Hall A + B Centre for the Development of Therapies for Civilization and Age-Related Diseases (CDT-CARD) – a new R&D division of the Jagiellonian University Medical College
Mission, opportunities, perspectives
Paweł Link-Lenczowski, PhD, Bartosz Pomierny, PhD, Tadeusz Karcz, PhD
Jagiellonian University Medical College, Kraków, Poland
3.15 – 3.30 p.m. – Medium Hall A + B Closing & Award ceremony – Medium Hall